MEI Pharma rides wave of interest in AML

January 26, 2017 Christoph Graener

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic heading into Phase III with Swiss partner Helsinn. Phase II data presented at the American Society of Hematology meeting in December 2016 suggested a complete response rate of 42% and median survival of 19.1 months for the drug in combination with Celgene’s Vidaza (azacitadine) in older, treatment-naive AML patients, which compares well to historical controls. Gold discussed his company’s plans for a large Phase III study with Helsinn and implications for interest in subtypes of the disease during an interview at Biotech Showcase.

Interviewer: Emily Hayes – Senior Writer, Scrip and The Pink Sheet
Interviewee: Dan Gold – President and CEO, MEI Pharma

Previous Article
CBMG aims for large-scale CAR-T capacity

CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large sca...

Next Article
Flexion gears up to commercialize Zilretta

Flexion CEO Mike Clayman shares expectations for regulatory review of recently-filed Zilretta for knee oste...